Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
12,083 total articles
Slide Insurance Holdings President and COO Lucas Shannon sold 23,493 shares on March 24 and March 26, 2026, realizing about $423,581. The transactions were executed through Securus Risk Management, LLC. The stock had advanced over 10% in the prior week. Separately, Slide Insurance reported stronger-than-expected fourth-quarter results, completed a …
Olivia Nottebohm, chief operating officer at Box, Inc., sold 5,942 shares of Class A common stock on March 25, 2026, under a Rule 10b5-1 plan. The trade, executed at $24.10 per share, totaled $143,202. The transaction follows a six-month, 26% decline in Box shares, which were trading at $23.82 at the time of reporting. Separately, Box reported quar…
F5, Inc. President, CEO and Director Francois Locoh-Donou sold 3,334 shares of common stock on March 25, 2026, for $300 per share, generating proceeds of $1,000,200. The transaction was executed under a Rule 10b5-1 trading plan established on December 3, 2025. F5 reported stronger-than-expected first-quarter 2026 results and unveiled multiple produ…
F5, Inc. Chief Financial Officer Werner Edward Cooper sold 1,000 shares on March 25, 2026, for $300.00 per share, totaling $300,000. The transaction was carried out under a prearranged Rule 10b5-1 plan dated December 3, 2025. Following the sale, Cooper directly holds 4,305 shares. The sale occurred near the stock's prevailing price and after a quar…
Village Farms International President of Canadian Cannabis Orville Bovenschen disposed of 50,000 common shares on March 25, 2026, in multiple open-market trades totaling $144,500. The sale was reported on a Form 4 filing. The transaction comes amid a fourth-quarter 2025 earnings miss and a market price that trades below analyst fair value ranges.
Peter Altman, President and CEO of BioCardia, Inc. (NASDAQ: BCDA), purchased 900 shares across two days in late March 2026 for a combined $1,110. The trades slightly raise his direct stake to 274,766 shares while the company reports modestly wider expenses and a net loss as it advances its CardiAMP therapy and engages with regulators.
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, sold 26,552 shares on March 25, 2026, in transactions totaling roughly $3.5 million and exercised options to acquire an additional 37,450 shares. The stock has posted strong gains over recent periods but is flagged by InvestingPro as overvalued versus its Fair Value. R…
Acadia Pharmaceuticals Chief Financial Officer Mark C. Schneyer sold 7,385 shares between March 25 and March 26, 2026, to cover withholding taxes tied to vested restricted stock units. The transactions generated approximately $159,135 in proceeds. Schneyer also received 14,316 shares on March 24 and 25 upon RSU vesting. The company recently reporte…
James Kihara, Acadia Pharmaceuticals' Principal Accounting Officer, disposed of 1,942 shares valued at $41,895 between March 25 and March 26, 2026. The sales, undertaken to satisfy withholding tax obligations, came immediately after restricted stock units vested and converted into 3,769 shares on March 24 and 25. The stock trades at $21.47, with a …
Andrew Bialecki, Co-CEO of Klaviyo Inc. (KVYO), sold 200,000 Series A shares on March 24, 2026, for $3.634 million under a pre-established Rule 10b5-1 trading plan. The transaction coincided with a conversion of 200,000 Series B shares into Series A and follows a roughly 40% drop in Klaviyo's stock over six months. The company has also announced a …
Acadia Pharmaceuticals CEO Owen Adams Catherine sold 11,641 shares on March 25, 2026, at $21.47 per share, generating approximately $249,932. The sale followed the conversion of 23,509 restricted stock units to common shares on March 24, 2026. Acadia's shares are down about 20% year-to-date but up roughly 25% over the past year. Additional corporat…
Jennifer J. Rhodes, Executive Vice President, Chief Legal Officer and Secretary of Acadia Pharmaceuticals, sold 3,844 shares of the company's common stock on March 25, 2026, raising $82,530. The sale followed an exercise of options for 7,515 shares at no cost on March 24, 2026. Acadia is trading below its InvestingPro Fair Value even as the company…
Elizabeth H.Z. Thompson, Executive Vice President and Head of Research & Development at Acadia Pharmaceuticals, disclosed an option exercise and subsequent sale that generated roughly $73,749. The trades were reported on a Form 4 and follow corporate developments including a regulatory negative opinion on trofinetide in Europe, a brokerage upgrade,…
Datavault AI Inc. Director Stanley Mbugua, who also serves as the company's Chief Accounting Officer and VP of Finance, sold 50,463 shares on March 24, 2026, for about $3,164 to satisfy tax obligations from vesting awards. The sale was non-discretionary, according to a Form 4 filing. Datavault reported its first GAAP profitable quarter in Q4 2025 e…
Datavault AI Inc.'s CEO Nathaniel T. Bradley sold 190,291 shares on March 24, 2026 to cover tax obligations tied to vested equity awards, while his spouse disposed of an additional 51,710 shares. The transactions coincided with a steep decline in the company's share price from its 52-week high, and follow recent corporate developments including a G…
Brett Moyer, Datavault AI's chief financial officer, disposed of 159,968 shares of common stock on March 24, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The sale generated $100,299 at a weighted average price of $0.627 per share and was executed to satisfy tax obligations tied to the vesting of equity awards. The …
PBF Energy Inc.'s senior legal executive, Trecia M. Canty, executed a sale of 62,999 Class A shares on March 24, 2026, for $50.00 each, generating $3.15 million, and on the same day exercised options to purchase 62,999 shares at $21.38 each. The company reported adjusted Q4 2025 EPS of $0.66, beating forecasts, while revenue narrowly trailed expect…
Adaptive Biotechnologies Corp's President and COO sold 57,180 shares between March 24 and March 26, 2026 under a pre-arranged 10b5-1 plan, generating about $802,235. She simultaneously exercised options to acquire 44,166 shares at $7.27 apiece for $321,086. The company recently reported stronger-than-expected fourth-quarter 2025 results and receive…
Rubrik Chief Financial Officer Choudary Kiran Kumar sold 122,613 Class A shares on March 24, 2026, generating $5.91 million, and converted 212,188 Class B shares to Class A the same day. The transaction occurred while the stock traded near a 52-week low. Separately, Rubrik reported quarterly results and guidance that topped FactSet consensus and in…
Rubrik Chief Technology Officer Arvind Nithrakashyap sold 28,967 shares of Class A common stock on March 24, 2026, for $48.1957 per share, netting $1,396,084. The same day he converted 40,625 Restricted Stock Units into shares at no cost. The stock is trading close to its 52-week low, while the company has reported quarterly results and forward gui…
David Raben, chief medical officer of Bicara Therapeutics Inc (NASDAQ: BCAX), sold 5,500 shares of the company's common stock on March 25, 2026, for about $104,229 while simultaneously exercising options to acquire an equal number of shares at a substantially lower strike. The transactions occurred just days ahead of Bicara's March 30 earnings repo…
DXP Enterprises director Timothy P. Halter sold 5,000 shares of the company’s common stock on March 26, 2026, at $139.57 per share, yielding $697,850. The transaction occurred while the stock traded near $137.06 after a roughly 60% gain over the prior year. The company reported mixed fourth-quarter fiscal 2025 results, missing EPS expectations but …
Magnetar Financial LLC, a 10% stakeholder in Wheeler Real Estate Investment Trust, sold 8,840 shares of WHLR common stock on March 26, 2026, at a weighted average price of $1.0964 for a total of $9,692. The transaction follows a March 24 acquisition of 172,075 shares at $0.01 and the disposition of a matching number of warrants. The sale and owners…
Definium Therapeutics Chief Legal Officer Mark Sullivan sold 10,702 common shares on March 25, 2026, under a Rule 10b5-1 plan to satisfy withholding tax obligations tied to vested restricted stock units. The transaction generated $197,665 at a weighted average price of $18.47 per share. Definium's recent fourth-quarter 2025 results showed heavy inv…
Definium Therapeutics Chief Executive Officer Robert Barrow sold 24,431 shares on March 25, 2026, for about $451,240 at weighted average prices between $18.36 and $18.80. The transaction, made under a Rule 10b5-1 plan adopted in 2022, was executed to meet withholding tax obligations related to vested restricted stock units. The stock is trading nea…
